Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam for Self-Injurious Behavior in Lesch-Nyhan Disease
NCT01751802Phase 3Terminated
- Sponsor
- Emalex Biosciences
- Start
- Dec 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ecopipam in Lesch-Nyhan syndrome (LNS), sponsored by Emalex Biosciences. Started Dec 2012; status: terminated.
02
Drugs
ecopipam
03
Conditions
Lesch-Nyhan syndrome (LNS)
Beyond the preview
Go deeper on NCT01751802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01751802.